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1 |  INTRODUCTION
Goiter is one of the rare causes of head and neck masses in 
newborns, which is observed in one case per 40 000 births.1 
This complication in infants is often associated with congeni-
tal hypothyroidism (CH), which can be caused by a hereditary 
problem or some nonhereditary causes such as monogenesis, 
or maternal antibodies and antithyroid drugs passing through 
the placenta.2 In a few cases, the disorder can be caused by 
excessive iodine that mother intakes.
Congenital hypothyroidism can be diagnosed during 
pregnancy or at birth.3 Sometimes the thyroid size at birth 
is not too large to be noticed, and sometimes its largeness 
can cause severe respiratory symptoms at birth, requiring in-
tubation.4 Hard vaginal delivery is observed in cases with a 
large thyroid. The most important disorder associated with 
CG is hypothyroidism and if it is left untreated leads to many 
disorders and consequently, cretinism.5 For this reason, the 
rapid diagnosis of CG, and the examination of thyroid hor-
mone status, is highly important for preventing the complica-
tions resulting from thyroid enlargement as well as hormonal 
changes.
Ultrasonography is the main diagnostic method of CG, 
which often displays homogeneous size in the thyroid. 
Furthermore, ultrasonography can examine thyroid pres-
sure on other neck organs as well as their displacement.5 In 
some cases, thyroid enlargement is detectable in ultrasound 
examinations during pregnancy.6 In some centers, after the 
diagnosis of goiter in the womb, fetal thyroid hormones are 
examined and the fetus is treated, if necessary.7 Care should 
be taken in case of a goiter diagnosis during pregnancy, and 
the medical team should be ready to the care for the baby at 
birth. If there is no severe respiratory complication, levothy-
roxine is prescribed. In this regard, the thyroid enlargement 
gradually disappears. Moreover, neonates with CG and CH 
should be monitored regularly and their dosage should be 
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Abstract
Congenital goiter (CG) is one of the rarest disorders observed in a newborn at birth 
diagnosed with hypothyroidism. Considering the simultaneity of pregnancy and ba-
by's hypothyroidism at birth, the goiter can be caused by diabetes during pregnancy 
and hypothyroidism emergence in the baby.
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adjusted for thyroid hormone status as well as thyroid-stim-
ulating hormone (TSH).8 Because of the rareness of this dis-
ease, few cases have been reported in the world. The present 
study introduced a case of cervical mass at the birth in a neo-
nate in the north of Iran followed up by a CG diagnosis.
2 |  CASE REPORT
Our patient was a 38-week-and-5-day-old boy born through 
cesarean due to fetal distress. He was weighted 2580  g at 
birth, first-minute and fifth-minute Apgar were 9 and 10, and 
amniotic fluid was transparent. The infant was admitted to 
the NICU ward for tachypnea and respiratory distress. The 
examination of the infant showed swelling in the anterior 
neck, which was mildly palpable and no subcutaneous em-
physema was seen. An intercostal retraction was seen on both 
sides of the chest and there was no deformity. The lungs were 
clean. No murmurs or excessive sound was heard on cardiac 
examination. Other newborn examinations were also normal.
The infant underwent ultrasonography for the diagnosis of 
a neck mass. Ultrasound showed a homogeneous echogenic 
soft tissue mass with markedly increased vascularity that was 
symmetrically on the chip. The mass was 55 × 20 mm. Goiter 
was diagnosed based on a mass profile (Figure 1). Thyroid 
hormones were measured to evaluate thyroid function (re-
sults of neonatal screening for CH) T4  =  4.39 micg/dL, 
FT4 = 1.1 ng/dL, FT3 = 4.1 pg/mL, and TSH = 15.9 m IU/L, 
respectively (Table 1). Parents did not agree for any further 
genetic investigations.
The infant's mother was 27  years old from Sari, 
Mazandaran, Iran. She had no past medical history of thy-
roid or any autoimmune disease. The baby was born from her 
third pregnancy. The previous two pregnancies had resulted 
in miscarriage, and the baby was the mother's first living 
child. The cause of the mother's two previous miscarriages 
was not mentioned, and the presence of “goiter” in the two 
previous pregnancies was unclear. During pregnancy, the 
mother had gestational diabetes and underwent diet therapy. 
History did not detect any other problems during pregnancy. 
Postnatal maternal thyroid function was T4 = 8.4 micg/dL 
and TSH  =  1.63  m  IU/L. The mother had consumed io-
dine-containing salt during pregnancy. Received supplements 
and vitamins during pregnancy were identified and did not 
contain iodine. Ultrasounds were normal during pregnancy 
and showed no mass at the site of the fetal neck. The baby's 
parents were not relative.
Immediately after the diagnosis, levothyroxine was ad-
ministered orally at the time of diagnosis for 40 micrograms 
per day. The infant was followed up monthly and TSH and 
free T4 levels were measured at each visit, and the dose of 
the drug was adjusted based on hormone levels. The baby's 
TSH was normal in the second to fifth months but increased 
again in the sixth month when the drug was modified. After 
6 months of the follow-up, ultrasound was performed for the 
infant and the size of the normal thyroid was reported. After 
6 months, the baby was 6500 g in weight. The infant's growth 
status was normal during the 6 months and equaled the 25th 
percentile.
3 |  DISCUSSION
Congenital goiter is a rare disease at birth and during preg-
nancy. This complication can cause polyhydramnios, tracheal 
and esophageal deformities during pregnancy, decreased in-
trauterine growth, and even fetal death.9 This disease mostly 
arises from the primary hypothyroidism in the fetus when 
the mother does not take antithyroid drugs, excessive iodine 
intake, or have no Graves’ or Hashimoto's disease. In gen-
eral, CG is observed in about 10% of CH cases.10,11 At birth, 
a fetus with goiter may have severe respiratory symptoms, 
which requires intubation.4
According to the study of Mirsaeid Ghazi et al, the 
CG reported in Iran was seen in only one case,12 which 
was related to a 34-week fetus with goiter. The mother 
was 33  years old and had no history of thyroid disease. 
The reported fetus was born from the third pregnancy. 
Neonates in both previous pregnancies had CG. The first 
baby, born after a cesarean section due to the poor fetal 
F I G U R E  1  Ultrasound neck mass image




T4 4.39 micg/dL 4.2-14
TSH 15.9 m IU/L 0.5-5.5
FT3 4.1 Pg/mL 2.2-4.2
FT4 1.1 ng/dL 0.8-1.7
   | 2675MEHRPISHEH Et al.
status, had respiratory problems and died immediately after 
the birth due to thyroid pressure on the trachea. The sec-
ond baby had CG and CH, and was accurately treated. She 
was 8 years old at the time of reporting and had a normal 
physical and educational status, but despite appropriate 
treatment, she still had a goiter. At the time of the third 
maternal pregnancy and considering previous pregnancies 
at 34 weeks of pregnancy, fetal thyroiditis was assessed by 
ultrasound, and goiter was observed. Maternal thyroid size 
and function were normal during pregnancy, and the fetus 
had no problems during the second ultrasound. However, 
amniocentesis was performed as requested by the parents 
and a dose of levothyroxine injected into the amniotic cav-
ity. Levothyroxine injections were also given weekly in 
three successive weeks and the infant was finally born at 
38 weeks. There was no clear thyroid enlargement at the 
birth, but radiography of knee did not show epiphyseal 
growth of femoral and tibial bones. The infant had been 
treated with levothyroxine and was examined on a monthly 
basis.12
Similar to the study of Mirsaeid Ghazi et al, the infant in the 
present study was born from the third pregnancy. The previ-
ous two pregnancies resulted in a miscarriage. Unfortunately, 
the age and the cause of miscarriage, and premiscarriage 
studies were unavailable, and we are not sure if previous em-
bryos also had a goiter. Ultrasound scans revealed no thyroid 
enlargement during pregnancy and no lesions such as polyhy-
dramnios. The mother did not have any prior thyroid disease 
before and during pregnancy and did not take any antithy-
roid medication but had gestational diabetes and underwent 
dietary treatment. Several studies have shown a relationship 
between gestational diabetes mellitus (GDM) and CH.13 A 
statistically significant association of CH was observed with 
birth defects, female gender, gestational age >40 weeks, and 
GDM. 14 In another population-based case-control study in 
Italy, the results also showed that GDM was a risk factor for 
CH.15 Few studies have investigated the presence of ThyAb 
in women with gestational diabetes mellitus (GDM), al-
though CH appears to be a multifactorial problem depending 
on genetic and environmental factors in the fetus, it is not 
clear that in our infant, only GDM causes CG and CH.16 The 
finding of raised TSH in GDM fetus as compared to control 
shows that it could not be due to Immaturity of fetal HPT 
axis or transient hypothyroidism of prematurity which is not 
possible as gestational age was appropriate (37 weeks). There 
are studies which demonstrated that pregnant women with in-
creased risk of GDM have a high prevalence of raised ThyAb 
[thyroid antibody] than observed in general women popula-
tion. However, few studies have reported no association be-
tween diabetes in pregnancy and thyroid function [ThyAb) in 
pregnant women with GDM.17,18
Another factor that may affect the incidence of CG in 
the studied neonate is the consumption of iodine-containing 
salts and iodine intake beyond the standard limit. In Iran, due 
to the high prevalence of hypothyroidism, especially in the 
north part of the country, iodine-containing salts were rec-
ommended to the people many years ago and most iodized 
salts were added. Although there have been few cases of 
maternal iodine intake in CG cases around the world, this 
should be taken into account. In one study, eight infants with 
CG whose mothers had high-iodine intake were identified. 
Increasing iodine intake leads to an increase in intrathyroi-
dal iodine concentration and a decrease in organogenesis and 
thyroid hormone. This mechanism, which occurs due to the 
preservation of life and the prevention of overproduction of 
thyroid hormone, can gradually decrease thyroid hormone 
and goiter.19 In another study, three newborns with CG were 
identified who were not initially positive for their cause, but 
further studies revealed that both mothers had taken high-io-
dine herbal remedies.20
During pregnancy, the fetus uses maternal thyroid hor-
mones at the beginning, and before the full formation of 
the thyroid gland and in ultrasound taken at 20-36  weeks 
of gestation, thyroid size and cervical mass are examined. 
Measurement of thyroid hormones and TSH by cordocente-
sis is the key standard method of determining hypothyroid-
ism during pregnancy,4 but amniocentesis is commonly used 
to diagnose fetal hypothyroidism due to its complications.21 
Although hypothyroidism can be diagnosed and treated after 
birth in a newborn, the disease can possibly affect mental de-
velopment during the embryo. For this reason, some sources 
recommend checking fetal thyroid hormones, and treatment is 
initiated in the case of a diagnosis of fetal goiter during preg-
nancy. Some sources recommend the intra-amniotic injection 
of levothyroxine in a fetus with embryonic goiter.1,11,22
Of course, this is not yet approved by international or-
ganizations and associations, and the American Thyroid 
Association (ATA) recommends thyroid hormone measure-
ment even in high-risk mothers 2-5 days after birth. One of 
the recommendations of this association is that in infants who 
are likely to be born with CH, the neonatal specialist should 
monitor the condition of the baby before delivery. Further, 
the American Academy of Pediatrics (AAP) recommends hy-
pothyroidism at a postnatal time, and only in mothers with a 
history of autoimmune thyroiditis or a previous history of an 
infant with CH, cordocentesis is considered one of the diag-
nostic methods but does not emphasize it.23 Thus, although 
studies in Iran show that the prevalence of CH in some parts 
of the country is ten times more than the global level and has 
been reported in the range of 1 per 1000 to 1 per 375 neo-
nates,23 monitoring fetal hormones and intrauterine treatment 
have not yet been confirmed for high-risk mothers.
Fetal endocrine system functions largely independent of the 
mother but maternal endocrine disorder can influence the fetus 
adversely. A relationship between GDM and thyroid hormone 
exist but yet to be established. The finding of raised TSH in 
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GDM fetus as compared to control shows that it could not be 
due to immaturity of fetal HPT axis or transient hypothyroid-
ism of prematurity which is not possible as gestational age was 
appropriate (37 weeks). There are studies which demonstrated 
that pregnant women with increased risk of GDM have a high 
prevalence of raised ThyAb (thyroid antibody) than observed 
in general women population. However, few studies have re-
ported no association between diabetes in pregnancy and thy-
roid function (ThyAb) in pregnant women with GDM.17,18
Considering that our study was one of the first CG studies 
in Iran and the Middle East, further studies are needed to in-
vestigate the incidence of this disorder in neonates. As in the 
present study, the mother had a history of two miscarriages, 
and in the study of Mirsaeid Ghazi et al, the first case re-
sulted in death and the second case underwent the treatment, 
and further studies in mothers who have had CG pregnancies 
or mothers who have had miscarriages for unknown reasons 
may be added to CG examinations.
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